Tc-99m MIBI Thoracic SPECT for the Detection of Intrathoracic Tumor Masses
Authors:
- Amita RastogiARAmita Rastogi
- Vicki StippVSVicki Stipp
- Kelly K. GrossKGKelly K. Gross
- John J. CoupalJCJohn J. Coupal
- Sylvia MagounSMSylvia Magoun
- 1 September 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 23 (9) , 594-600
Abstract
Thirty-one men (age range, 46-76 years; mean age, 64.8 years) with intrathoracic masses suggesting possible malignancy on the basis of chest radiography or CT underwent preoperative Tc-99m MIBI SPECT examinations. Diagnosis was confirmed on pathologic examinations of samples obtained either at thoracotomy, esophagectomy, or by biopsy. Twenty-five patients had primary lung cancer, including squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and small cell carcinoma. Two patients had lymphomas with spread to the mediastinum, and three patients had extrathoracic primary cancers (one squamous cell carcinoma of esophagus, one squamous cell carcinoma originating from a head and neck tumor, and one metastatic mediastinal leiomyosarcoma). One patient with a tuberculoma had negative results of the Tc-99m MIBI examination. Tc-99m MIBI had a 86.7% sensitivity rate, a 0% false-positive rate, and a 100% positive predictive value to detect malignant intrathoracic masses. There was a 13% false-negative rate, however, suggesting that MIBI-SPECT may underdiagnose malignant lesions. SPECT findings of these 31 patients can be classified as 1) mass with increased uptake, n = 23; 2) ring-like appearance of increased uptake, n = 3; 3) mass with absent uptake, n = 4; and 4) photon-deficient mass, n = 1. Absent uptake in patients with mass lesions could be explained by necrosis of the lesion (caseation necrosis or massive tumor necrosis with or without bleeding). Most malignant intrathoracic masses are Tc-99m MIBI avid and may be detected with a high degree of sensitivity and with an excellent positive predictive value. A positive MIBI scan may help in the clinical diagnosis of malignancy. The use of Tc-99m MIBI could serve not only as a tumor imaging agent, but also may be used to determine the extent of spread and potentially the chemotherapeutic responsiveness of a tumor.Keywords
This publication has 14 references indexed in Scilit:
- A Large Photon-Deficient Area in the Right Thorax on Tc-99m MIBI Thoracic SPECT Resulting From a Rapidly Enlarging LeiomyosarcomaClinical Nuclear Medicine, 1996
- 99Tcm-MIBI mammoscintigraphy of breast masses: Early and delayed imagingNuclear Medicine Communications, 1995
- Liver Metastases Detected by Tc-99m Sestamibi During Routine Cardiac ImagingClinical Nuclear Medicine, 1995
- Clinical Experience with Tc-99m MIBI Imaging in Patients with Malignant Tumors Preliminary Results and Comparison with TI-201Clinical Nuclear Medicine, 1992
- Effectiveness of planar image and single photon emission tomography of thallium-201 compared with gallium-67 in patients with primary lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 1992
- Quantification of area at risk during coronary occlusion and degree of myocardial salvage after reperfusion with technetium-99m methoxyisobutyl isonitrile.Circulation, 1990
- Effect of ischemia and postischemic dysfunction on myocardial uptake of technetium-99m-labeled methoxyisobutyl isonitrile and thallium-201JACC, 1989
- Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humansEuropean Journal of Nuclear Medicine and Molecular Imaging, 1989
- Uptake and Kinetics of Tc-99m Hexakis 2-Methoxy Isobutyl Isonitrile in Benign and Malignant Lesions in the LungsClinical Nuclear Medicine, 1989
- Expression of a multidrug-resistance gene in human tumors and tissues.Proceedings of the National Academy of Sciences, 1987